Exclusion criteria are presence of moderate to severe dementia and acute concurrent abuse or dependence on substances other than alcohol (with the exception of caffeine and nicotine). Thus far, 180 alcoholics (144 men, 36 women) have been treated with a 7-year follow-up see more success rate of over 50% abstinent patients despite a “negative selection,” with regard to severity of alcohol dependence, comorbidity, and social detachment, upon entering the program. Patients were on average 44±8 years old, had a duration of alcohol dependence of 18±7 years, approximately Inhibitors,research,lifescience,medical 7±9 prior inpatient detoxification treatments, and

1±1 failed inpatient long-term therapy. Almost 60% of the patients were unemployed. Psychiatric comorbidity amounted to 80%. About 60% of Inhibitors,research,lifescience,medical the patients suffered from severe sequelae of alcoholism, such as polyneuropathy, chronic pancreatitis, or liver cirrhosis. To illustrate addiction severity in our population, representative scores of the European Addiction Severity Index109,110 were 0.58 (±0.38) for medical status, 0.56 (±0.47) for economic status, 0.51 (±0.37) for job satisfaction, 0.83 (±0.11) for alcohol use, 0.59 (±0.30) for family relationships,

and 0.46 (±0.21) for psychiatric status. Long-term treatment outcomes Considering this severely Inhibitors,research,lifescience,medical affected population of alcoholics, the long-term success rate of OLITA is incredibly high: More than 50% of the patients remain abstinent over up to 7 years of post-treatment

follow-up (Figure 1). Based on this high abstinence rate, a tremendous improvement in psychological, biological, and social Inhibitors,research,lifescience,medical parameters of this patient group could be achieved. The unemployment rate of OLITA patients declined Inhibitors,research,lifescience,medical to 22% in an area (Göttingen) with a general unemployment rate of 17% (Figure 2). and the comorbid psychiatric disorders anxiety and depression decreased from approximately 60% to 13%. 76,94 Additionally, patients had a clear decrease in physical sequelae of alcoholism, ranging from liver disease to polyneuropathy Figure 3 a, b and c illustrate the highly significant reduction in psychiatric comorbidity Shown are all comorbid disorders (Figure 3a), anxiety disorders (Figure 3b), and mood disorders (Figure 3c) in percentage of the study population Cediranib (AZD2171) from month 1 of therapy to 2 years, ie, the termination of the program. The global decrease of comorbid disorders during therapy is characterized by two specific features of the recovery process. Firstly, anxiety disorders show a delayed remission, ie, they do not change significantly until the first year of therapy. Secondly, the early remission of mood disorders during the first 6 months harbors the risk of reccurence of major depression during long-term abstinence.